Skip to content

The US equity market’s ascent paused in October as investors digested rising rates, slowing global growth and the persistent question: “Are things as good as they’ll get?” As many observers expect further turbulence ahead, Franklin Equity Group’s Grant Bowers shares his view on US equities, the economy, and how to stay focused on long-term investing in a volatile market.

The US bull market continues to confound fears of its demise.

While we’ve seen some wobbles in October, we don’t see a reason to believe the market will be thrown off course. But the longer the bull run lasts, the more investors are asking: “Are things as good as they’ll get?”

Two Pillars for Optimism

On a macro level, we remain optimistic in our US market outlook. Looking at what drives US companies and the economy in general, we see two main pillars: corporations and consumers. Both remain healthy, in our view.

US corporations continue to generate earnings growth rates above global peers, while domestically, unemployment is low, consumer confidence is high, and wages are starting to increase. We don’t see the selloff in equities at the end of October as being a precursor to a larger economic recession but more of a recalibration as the market assesses the changing global landscape.

With the recent selloff, valuations have come down and, in our view, are at a level that accurately reflects the investment environment. Strong earnings, coupled with the pricing pullback earlier this year, suggests to us that things don’t look too bad on a price-to-earnings ratio.1

US economic growth, profit margins and stock returns are still well above global peers.

Inflation is creeping up in the United States, but appears relatively anchored. Growth has been robust but not too fast. In our view, there are no signs of the credit imbalances or excesses that often lead to overheating.

How We Approach The Ageing Bull Market

For us, investing in an ageing bull market like we are in today isn’t that much different than any other time. We remain focused on building a portfolio of stocks that we believe should be poised to benefit from multi-year secular growth themes or innovation.

We take a long-term view and leverage our bottom-up research to identify businesses that have dominant brands or franchises with high-quality management teams and healthy financial returns.

Consequently, our analysis encompasses more than just the current cycle; we consider a potential investment’s outlook for the next 5-10 years.

As long-term investors, we are always trying to block out the short-term market noise and identify sectors and companies that are benefitting from large multi-year growth trends.

We look for secular growth stories that are disrupting incumbent businesses and are addressing the major needs of tomorrow.

Seeking Out Disruption and Innovation

We really want to hone in on the changes that are occurring today that will impact the world tomorrow. Often these growth trends are driven by disruptive technologies, innovation, changing consumer habits or demographic shifts.

This includes things like demographics, digitisation—including e-commerce and the cloud—as well as artificial intelligence.

There is likely to be a tremendous amount of change taking place in the technology and health care sectors in particular over the next few years.

Our Positive Outlook for Technology and Health Care

In the technology sector, the outlook for spending remains strong as many companies have realised that investments in technology improvements are required to remain competitive in the global marketplace.

New software, factory automation and data analytics can all improve productivity and lower the cost of production for companies, keeping them ahead of their competitors.

Cybersecurity, software as a service (SaaS), cloud computing, digital payments, mobility and smart devices are just some of the technological areas that have sparked our interest.

Similarly, we continue to look favourably on the long-term outlook for the health care sector. We expect an ageing population globally to drive increased consumption of health care services and demand for improved treatments and cures.

This demographic tailwind, combined with innovation in drug development and medical technology, is creating numerous potential investment opportunities as well.

Overall, our long-term outlook for both technology and health care companies remains positive. While both sectors have traditionally experienced bouts of short-term volatility, those have often created attractive buying opportunities for many investors.

To hear more from Grant Bowers on the US market, including his thoughts on the three biggest risks and the growth versus value debate, check out this episode of our Talking Markets podcast.

The comments, opinions and analyses expressed herein are for informational purposes only and should not be considered individual investment advice or recommendations to invest in any security or to adopt any investment strategy. Because market and economic conditions are subject to rapid change, comments, opinions and analyses are rendered as of the date of the posting and may change without notice. The material is not intended as a complete analysis of every material fact regarding any country, region, market, industry, investment or strategy.



Copyright ©2025. Franklin Templeton. All rights reserved.

This document is intended to be of general interest only. This document should not be construed as individual investment advice or offer or solicitation to buy, sell or hold any shares of fund. The information provided for any individual security mentioned is not a sufficient basis upon which to make an investment decision. Investments involves risks. Value of investments may go up as well as down and past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD (“other foreign currency”). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

The data, comments, opinions, estimates and other information contained herein may be subject to change without notice. There is no guarantee that an investment product will meet its objective and any forecasts expressed will be realized. Performance may also be affected by currency fluctuations. Reduced liquidity may have a negative impact on the price of the assets. Currency fluctuations may affect the value of overseas investments. Where an investment product invests in emerging markets, the risks can be greater than in developed markets. Where an investment product invests in derivative instruments, this entails specific risks that may increase the risk profile of the investment product. Where an investment product invests in a specific sector or geographical area, the returns may be more volatile than a more diversified investment product. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from use of this document or any comment, opinion or estimate herein. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Any share class with “(Hedged)” in its name will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

Please contact your financial advisor if you are in doubt of any information contained herein.

For UCITS funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the UCITS Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

For AIFMD funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the AIFMD Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 32a of the AIFMD Directive.

For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund(s)/ sub-fund(s) and will not be investing directly in the underlying assets of the fund(s)/ sub-fund(s).

This document is issued by Franklin Templeton Investments (Asia) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.

Unless stated otherwise, all information is as of the date stated above. Source: Franklin Templeton.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.